Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

SYNTEX NAPROSYN CONSENT DECREE MANDATES FULL DISCLOSURE of all financial or material assistance provided by the company for public presentations of promotional or educational materials about the drug. Under the consent decree with FDA filed in San Francisco federal court on Oct. 10 ("The Pink Sheet" Oct. 14, p. 6), Syntex agreed to a package of actions to correct false or misleading advertisements and/or promotions for the nonsteroidal anti- inflammatory Naprosyn (naproxen). Under the consent decree, Syntex has to preclear all its ad and promotional materials with FDA for the next two years. In addition to the FDA scrutiny of all promotional and educational materials and the public disclosure requirements, the consent decree mandates that Syntex run corrective ads in 18 medical journals and on "Lifetime" Medical Television where the false or misleading "arthroprotective"/disease remission ads for Naprosyn were placed and send out one quarter-million "Dear Doctor" corrective letters. With regard to public presentations, video news releases (VNRs) or educational symposia for Naprosyn, the consent decree requires that Syntex "secure an agreement from all persons" presenting material that they publicly disclose: "(a) the nature of their direct and indirect financial relationships with [Syntex] for three years prior to the presentation; and (b) the nature of any assistance or support" from Syntex. That support includes, but is not limited to, the "selection of topics, speakers, or points or emphasis, preparation of outlines, draft manuscripts or talks, audio-visual aids, and data presentations." Syntex also agreed to refrain from any promotional activity for Naprosyn in connection with any of these situations or else identify the events as a promotional event. FDA's disclosure demands on Syntex are representative of the agency's growing desire to make public all commercial affiliations between clinicians, researchers and companies. The Syntex agreement in this regard is less demanding than the agreement between Bristol Labs and the agency. Under that May agreement, FDA is seeking to have Bristol assure that all the affiliations of presenters at symposia sponsored by Bristol money be disclosed in the agenda for those meetings. Bristol maintains that it cannot exert that kind of control over meetings sponsored by third parties ("The Pink Sheet" Sept. 30, p. 8). Regarding other types of promotional materials, Syntex agreed to submit to FDA "at least 30 days prior" to use: a copy of all "proposed written, printed or graphic promotional materials ... including ... videotapes"; a description of all proposed "promotional meetings, special events, and instructions" (including training manuals) "for the use of promotional materials by sales and other representatives engaged in sales activities"; and a description of "all proposed educational, public relations, press and media materials, including video news releases, press kits, press releases, and similar materials, that provide information on the safety and efficacy of the drug." Media materials have to be presented to FDA only at the time of their dissemination.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts